Page last updated: 2024-08-21

pyrazines and Short Bowel Syndrome

pyrazines has been researched along with Short Bowel Syndrome in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gonzalez, ML; Gonzalez-Pinto, IM; Island, ER; Rossique, M; Ruiz, P; Selvaggi, G; Smith, LJ; Solano, JP; Tekin, A; Tryphonopoulos, P; Tsai, HL; Tzakis, AG	1
Gerlach, UA; Koch, M; Lachmann, N; Pascher, A; Schoenemann, C	1

Other Studies

2 other study(ies) available for pyrazines and Short Bowel Syndrome

Article	Year
Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation. Clinical transplants, 2009 Topics: Adrenal Cortex Hormones; Antilymphocyte Serum; Biopsy; Boronic Acids; Bortezomib; Child, Preschool; Female; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Intestines; Protease Inhibitors; Pyrazines; Short Bowel Syndrome; Tacrolimus; Treatment Outcome; Viscera	2009
Salvage therapy for refractory rejection and persistence of donor-specific antibodies after intestinal transplantation using the proteasome inhibitor bortezomib. Transplant international : official journal of the European Society for Organ Transplantation, 2011, Volume: 24, Issue:5 Topics: Antigens, CD20; Bone Marrow Cells; Boronic Acids; Bortezomib; Graft Rejection; Humans; Immunity, Humoral; Intestines; Middle Aged; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Short Bowel Syndrome; Syndecan-1; Transplantation, Homologous; Treatment Outcome	2011

Article

Year

Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation.

Clinical transplants, 2009

Topics: Adrenal Cortex Hormones; Antilymphocyte Serum; Biopsy; Boronic Acids; Bortezomib; Child, Preschool; Female; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Intestines; Protease Inhibitors; Pyrazines; Short Bowel Syndrome; Tacrolimus; Treatment Outcome; Viscera

2009

Salvage therapy for refractory rejection and persistence of donor-specific antibodies after intestinal transplantation using the proteasome inhibitor bortezomib.

Transplant international : official journal of the European Society for Organ Transplantation, 2011, Volume: 24, Issue:5

Topics: Antigens, CD20; Bone Marrow Cells; Boronic Acids; Bortezomib; Graft Rejection; Humans; Immunity, Humoral; Intestines; Middle Aged; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Short Bowel Syndrome; Syndecan-1; Transplantation, Homologous; Treatment Outcome

2011